Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.15 – $2.50
15% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $166.3M | $173.4M | $35.0M | $76.9M | $54.1M | $56.6M | $1.3M | $2.0M |
| Cost of revenue | $12.4M | $49.2M | $58.5M | $37.7M | $78.8M | $30.6M | $548.0K | $18.6M |
| Gross profit | $153.9M | $124.3M | −$23.5M | $39.2M | −$24.7M | $26.0M | $735.0K | −$16.6M |
| Gross margin | 92.6% | 71.7% | -67.1% | 51.0% | -45.6% | 45.9% | 57.3% | -842.7% |
| R&D | $143.5M | $126.0M | $109.1M | $213.3M | $267.1M | $216.8M | $302.4M | $387.7M |
| Operating income | −$133.9M | −$36.4M | −$217.1M | −$225.0M | −$344.0M | −$300.2M | −$295.4M | −$471.3M |
| EBITDA | −$131.4M | −$73.6M | −$181.9M | −$169.3M | −$284.5M | −$126.1M | −$390.4M | −$454.1M |
| Net income | −$7.3M | −$96.0M | −$209.2M | −$199.0M | −$314.8M | −$144.7M | −$300.9M | −$350.6M |
| Net margin | -4.4% | -55.3% | -597.8% | -258.9% | -582.1% | -255.7% | -23455.7% | -17745.6% |
| EPS (diluted) | -0.01 | -0.15 | -0.20 | -0.18 | -0.29 | -0.13 | -0.30 | -0.36 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $803M | $0.44 | $0.19–$0.68 | 1 |
| 2027 | $70M | $-0.35 | $-0.55–$-0.15 | 1 |
| 2028 | $173M | $-0.35 | $-0.56–$-0.15 | 1 |
Forward consensus · source: Financial Modeling Prep
ASCLETIS PHARMA INC
No one on the platform currently holds ASCLF.
No tracked institution reports a position in ASCLF as of their last filing.
No one on the platform has traded ASCLF yet.
| $497M |
| — |
| LJUIFSSY Group Limited | $0.40 | +0.00% | $1.2B | — |
| LTGHFLife Healthcare Group Holdings Limited | $0.81 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 13.3× sales vs its 10.0× historical median P/S.
Fair value ≈ $1.02 · price $1.35 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.